The alkaloid cryptolepine (1) and eight synthetic analogues (2-8) were assessed for in vitro activities against Trypanosoma brucei. Four of the analogues were found to be highly potent with IC 50 values of less than 3 nM and three of these were assessed against T. brucei brucei infection in rats. The most effective compound was 2, 7-dibromocryptolepine (7); a single oral dose of 20 mg/kg suppressed parasitaemia and increased the mean survival time to 13.6 days compared with 8.4 days for untreated controls. In addition, four huperzine derivatives (9-12) were shown to have in vitro antitrypanosomal activities with IC 50 values ranging from 303-377 nM.
The need for new drugs to treat human African trypanosomiasis is becoming increasingly urgent due to a resurgence of the disease coupled with widespread resistance of Trypanosoma species to the available drugs, which are outdated and often toxic to the patients [1] . The World Health Organisation estimates that nearly 60 million people in subSaharan Africa are at risk from this disease [2] and, in addition, trypanosomiasis in livestock is a major problem that severely limits economic development in rural Africa [3] .
Cryptolepine (1) is an indoloquinoline alkaloid ( Figure 1 ) found in the West African climbing shrub, Cryptolepis sanguinolenta Lindl. Schltr. (family Periplocaceae) [4] . The roots of this species are used traditionally for the treatment of malaria and for various other infectious diseases. A number of synthetic cryptolepine analogues have been evaluated for their potential as antimalarial agents and several have been found to have in vitro and in vivo antimalarial activities with enhanced potencies and reduced toxicities compared with the parent alkaloid [4, 5] . In order to explore the possibility that these compounds may exhibit antitrypanosomal as well as antiplasmodial activities, we have assessed cryptolepine and several analogues for in vitro and in vivo activities against Trypanosoma brucei, the parasite responsible for African sleeping sickness. Huperzine A is an alkaloidal constituent of the club moss, Huperzia serrata Thunb. ex Murray (family Huperziaceae), known in China as Qian Ceng Tang [6] . This species has been used in Chinese traditional medicine for over 1000 years for the treatment of various conditions, including myasthenia gravis, and is now of interest as a lead towards new drugs for the treatment of Alzheimer's disease on account of its acetylcholinesterase inhibiting properties. Huprines are synthetic derivatives of huperzine A that incorporate a 4-aminoquinoline moiety, which is also present in chloroquine and some related antimalarial agents. The in vitro trypanocidal activities of four huprine analogues are reported. The structures of the cryptolepine and huprine analogues examined in this study are shown in Figures 1 and 2 respectively.
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The in vitro activities of compounds 1-12 against T. brucei are shown in Table 1 , together with published antiplasmodial and cytotoxic activities for compounds 1-8. Cryptolepine (1) and its 11-chloro-analogue (6) were moderately potent against trypanosomes (IC 50 = 306 and 265 nM, respectively), while the 2-bromo-(2) and 2-fluoro- (8) analogues were approximately 7-and 4-fold more potent than cryptolepine, respectively (IC 50 = 40.3 and 78.0 nM respectively). In contrast, the 7-bromo-(3), 2-chloro-(4), 8-chloro-(5) and 2,7-dibromocryptolepine (7), analogues were all >100-fold more potent than 1, with IC 50 values ranging from 1.50-2.90 nM. Comparing the trypanocidal activities of these compounds with their published antiplasmodial activities [4, 5] , it is clear that with the exceptions of cryptolepine (1) and its 11-chloroanalogue (6), there is no correlation between activities against the two species of protozoa, although the most active antiplasmodial compound, 2,7-dibromocryptolepine (7) is also highly potent against trypanosomes. In order to assess the selectivity of these compounds against trypanosomes, their published cytotoxic activities against mouse adenocarcinoma of the colon (MAC15A) cells [4, 5] are shown in Table 1 , together with their selectivity indices (cytotoxic activity/ antitrypanosomal activity). Cryptolepine (1) and its less active analogues 2 and 8 exhibit relatively low selectivity against trypanosomes (selectivity indices 29.3, 144 and 50.8, respectively), while the potent trypanocidal analogues 4, 5 and 7 show high selective toxicity to trypanosomes (selectivity indices 8084, >3019 and 2083, respectively). It should be noted that in the cytotoxicity tests, compounds were incubated with the cells for 96 hours and that for cryptolepine analogues cytotoxicity is increased with a longer compound-cell exposure time [4] so that even higher selectivity indices would be expected if shorter exposure times were used.
In the case of the huprine analogues 9-12, all four compounds displayed similar and moderately potent activities against T. brucei (IC 50 ranging from 303-377 nM). Although these activities are considerably less than those of some of the cryptolepine analogues, only a small selection of huprine analogues has been assessed and it is possible that, as with the cryptolepine series, other analogues may exhibit more potent activities.
Three of the most potent cryptolepine analogues, 3, 5 and 7, were selected for evaluation against T. brucei brucei infection in rats, together with cryptolepine for comparison. The effects of i.m. and i.v. administration of single doses of 7-bromocryptolepine (3) and 8-chlorocryptolepine (5) on the parasitaemia in the blood of infected animals are shown in Figures 3 and 4 , respectively, and survival plots for 3 and 5 are shown in Figure 5 .
Compared to untreated controls, both compounds suppressed parasitaemia with both i.m. and i.v. administration. At day eight, 8-chlorocryptolepine (5), given i.m., showed the greatest suppression and increased the mean survival time from 8.7 days for untreated infected controls to 11.7 days, as seen in the survival plots ( Figure 5 ). Compound 5 (1) and 2, 7-dibromocryptolepine (7) on parasitaemia of rats infected with T. brucei brucei compared with untreated controls; blood parasitaemia was measured daily until the first death in each group.
given i.v., as well as 3 given by either route, did not significantly increase mean survival time. The most promising results were given by 2,7-dibromocryptolepine (7), which suppressed parasitaemia when given i.m., i.v. or orally ( Figure 6 ) and increased survival times to 13.4, 13.6 and 13.4 days, respectively, compared to untreated controls, which survived for only 8.4 days (Figure 7) . Cryptolepine (1) given i.m. delayed the increase in parasitaemia only slightly ( Figure 6 ) and animal survival was increased to only 9.6 days ( Figure 7 ).
These results indicate that there is a correlation between in vitro and in vivo antitrypanosomal activities and, in the case of 7, that this compound is absorbed orally at least to some extent, since survival was similar to that seen with parenteral administration. In the case of 7, parasitaemia was suppressed until the animals died (Figure 6 ), whereas a marked rise in parasitaemia (as seen with untreated control animals) would normally be expected prior to death; however, the explanation for this observation is not clear. The above results, especially for 7, appear to be promising considering that the above results were obtained with single doses (20 mg/kg) and further exploration of cryptolepine analogues as leads to new agents for the treatment of African trypanosomiasis would be worthwhile.
The mode of action of cryptolepine analogues as trypanocides is unknown. Cryptolepine (1) is a well known intercalator of DNA [7] , as well as an inhibitor of topoisomerase II and of DNA synthesis [8] , and it is possible that these properties may explain its moderate action against trypanosomes. Analogues 2, 3, 6 and 7 have been examined for their effects on the melting point of DNA (Δ Tm value) and all were found to have Δ Tm values of < 5˚C, whereas the Δ Tm value for 1 was found to be 9˚C indicating that in contrast to 1, these analogues are not likely to be DNA-intercalators [4] . The antiplasmodial action of cryptolepine may be partly due to interactions with DNA, but it has also been shown to have a chloroquine-like action (inhibition of haemozoin formation), that does not involve DNAintercalation. Analogues of cryptolepine that have antiplasmodial properties appear to act as inhibitors of haemozoin formation, but this is unlikely to be relevant in Trypanosomes as these organisms do not reside in red blood cells and/or digest hemoglobin.
As shown in Table 1 , the antiplasmodial and trypanocidal activities of the cryptolepine analogues do not parallel each other, especially for 5, that was inactive against malaria parasites, but has potent activity against trypanosomes. It is interesting to note that 7 has the most potent activities against both species of protozoa and also that the potent antiplasmodial activity of 7 cannot be explained entirely on the basis of the inhibition of haemozoin formation [5] . It is possible that the antiplasmodial and trypanocidal activities of 7 may share a common mechanism. Recently, a study investigating the effects of 1 on gene expression in the yeast Saccharomyces cerevisiae revealed that the expression of 349 genes was significantly affected by 1 at its IC 40 concentration (117 up-regulated and 232 down-regulated) [9] . While a general up-regulation of stress-related genes was observed, specific downregulation of genes related to iron transport and acid phosphatases also occurred and the possibility that similar effects may occur in protozoa would be worthy of exploration.
Conclusion:
This study has identified several analogues of cryptolepine (3, 4, 5 and 7) as potent and selective inhibitors of T. brucei in vitro with IC 50 values ≤ 2.9 nM. In mice infected with T. brucei 2,7-dibromocryptolepine (7) showed the most promising activity of the three analogues tested in vivo, both in terms of suppression of parasitaemia, as well as with respect to animal survival and, importantly, it was similarly active by oral, i.m. and i.v. routes of administration. The in vitro antitrypanosomal activities of these analogues do not parallel their antiplasmodial activities and their modes of action against the two species appear to be different, although this may not entirely be the case for 7. Further exploration of cryptolepine analogues and other natural product-derived agents, such as huprine derivatives as leads towards new antitrypanosomal agents would be worthwhile.
Experimental
Compounds: Cryptolepine (1) and the analogues 2-8 were synthesized as previously reported [4, 5] . Huprine X, (12) , (rac-12-amino-3-chloro-9-ethyl-6,7,10,11-tetrahydro-7,11-methanocycloocta[b]quinoline hydrochloride) [10] , huprine Y (11), (rac-12-amino-3-chloro-6,7,10,11-tetrahydro-9-methyl-7,11-methanocycloocta[b]-quinoline hydrochloride) [11] , the 9-allyl-substituted huprine (9), (rac-9-allyl-12-amino-6,7,10,11-tetrahydro-7,11-methanocycloocta[b] quinoline hydrochloride) [12] and the 9-isopropylsubstituted huprine (10), (rac-12-amino-6,7,10,11-tetrahydro-9-isopropyl-7,11-methanocycloocta[b] quinoline hydrochloride) [12] were available from previous work.
Assessment of in vitro activity against trypanosomes:
The tissue culture-adapted form of T. brucei (strain 427) was cultured in complete HMI-9 medium containing 10% fetal bovine serum and 10% Serum Plus medium (JRH Inc. Lenexa, KS, USA), using T-75 vented cap culture flasks (Greiner, Kremsmuenster, Austria) and maintained in a humidified incubator at 37˚C with 5% CO 2 , as previously described [13] . 8 10 2 trypanosomes per mL and each animal was inoculated with 80 trypanosomes (0.1 mL) intraperitoneally [14] . Animals were examined on a daily basis for parasitaemia by wet mount examination, as previously described [15] . On the day that 2-5 parasites were observed per microscopic field, animals were divided into groups of either 3 (for compounds 3 and 5) or 5 (for compounds 1 and 7), and each group of animals was treated with either a cryptolepine analogue (20 mg/kg) in 0.2 mL normal saline or DMSO given i.v., i.m. or orally. One group of animals served as a control group and was untreated. Parasitaemia was observed on a daily basis, as described above.
